Neuronetics (STIM) Stock Price, News & Analysis

Company Overview

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: $1.26 to $1.42
• 50-Day Range: $0.61 to $1.39
• 52-Week Range: $0.52 to $5.07
• Volume: 95,956 shs
• Average Volume: 294,293 shs
• Market Capitalization: $42.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.67
• Consensus Rating: Moderate Buy

Neuronetics Stock Analysis - MarketRank™

Neuronetics scored higher than 59% of companies evaluated by MarketBeat, and ranked 585th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Neuronetics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuronetics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuronetics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuronetics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.00% of the outstanding shares of Neuronetics have been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuronetics has recently decreased by 37.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuronetics does not currently pay a dividend.

Dividend Growth

Neuronetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.00% of the outstanding shares of Neuronetics have been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuronetics has recently decreased by 37.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.31

News Sentiment

Neuronetics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Neuronetics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,385.00 in company stock.

Percentage Held by Insiders

Only 9.80% of the stock of Neuronetics is held by insiders.

Percentage Held by Institutions

53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STIM Stock Analysis - Frequently Asked Questions

How have STIM shares performed this year?

Neuronetics' stock was trading at $2.90 at the beginning of 2024. Since then, STIM stock has decreased by 52.1% and is now trading at $1.39.
View the best growth stocks for 2024 here.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.06. The company had revenue of $16.45 million for the quarter, compared to analysts' expectations of $18.76 million. Neuronetics had a negative trailing twelve-month return on equity of 141.24% and a negative net margin of 50.09%.

When did Neuronetics IPO?

Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' top institutional shareholders include HighTower Advisors LLC (0.81%), GSA Capital Partners LLP (0.26%) and Landscape Capital Management L.L.C. (0.23%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, Stephen Furlong, Robert Cascella, William Andrew Macan and Glenn P Muir.
View institutional ownership trends.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), General Electric (GE), Intel (INTC), Bank of America (BAC) and Nokia Oyj (NOK).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:STIM
• CUSIP: N/A
• CIK: 1227636
• Web: www.neurostar.com
• Phone: (610) 640-4202
• Fax: 610-640-4206
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.67
• High Stock Price Target: $8.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +235.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,190,000.00
• Net Margins: -50.09%
• Pretax Margin: -50.09%
• Return on Equity: -141.24%
• Return on Assets: -32.77%

Debt

• Debt-to-Equity Ratio: 4.90
• Current Ratio: 3.16
• Quick Ratio: 2.87

Sales & Book Value

• Annual Sales: $72.71 million
• Price / Sales: 0.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.18 per share
• Price / Book: 1.18

Miscellaneous

• Outstanding Shares: 30,348,000
• Free Float: 27,374,000
• Market Cap: $42.18 million
• Optionable: Optionable
• Beta: 2.25